This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Apexigen Announces Initiation Of Clinical Trials By Its Partner, Simcere Pharmaceutical Group

BURLINGAME, Calif., Nov. 11, 2012 /PRNewswire/ -- Apexigen, an emerging biopharmaceutical company dedicated to the discovery and development of best-in-class therapeutic monoclonal antibodies, announced today that its partner, Simcere Pharmaceutical Group (NYSE:SCR) of Nanjing, received approval from the State Food and Drug Administration of China to begin first-in-man trials with APX003, which is also known as BD0801, for the treatment of cancer. With this approval, APX003/BD0801 becomes the first humanized monoclonal antibody derived from Apexigen's proprietary antibody technology platform to enter human trials.

APX003/BD0801 is being developed in China through an active partnership between Apexigen and Simcere.  Apexigen has collaborated with Simcere to add its antibody development expertise and experience to the advancement of the APX003/BD0801 program. This approval marks the success of the dedicated work of the collaboration team to file and defend an IND application, and initiates the next phase of collaboration in clinical development.

"We're very pleased to see the IND approval for APX003/BD0801.  This is an important milestone for our collaboration with Simcere and for proof-of-concept of our antibody technology platform" said Dr. Xiaodong Yang, President & CEO.  "We look forward to continuing the collaboration with Simcere and advancing AXP003/BD0801 into clinical development."

APX003/BD0801 is a humanized monoclonal antibody directed against VEGF and is under development for the treatment of multiple malignancies.

About Apexigen, Inc.Apexigen is a biopharmaceutical product development company advancing a pipeline of novel product candidates with the potential to address life-threatening and difficult to treat diseases. The company's proprietary technology platform enables the discovery and development of superior antibody product candidates that are able to impact previously inaccessible disease targets.

Apexigen is actively pursuing product development, both by itself and in collaboration with partners, with a focus in oncology. The company's product portfolio is comprised of humanized antibodies, targeting diseases such as cancer, inflammatory diseases and ophthalmic disease.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,596.35 -350.33 -1.95%
S&P 500 2,057.64 -43.85 -2.09%
NASDAQ 4,958.4680 -122.0370 -2.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs